Gyre Therapeutics (NASDAQ:GYRE) Shares Gap Up – What’s Next?

Gyre Therapeutics, Inc. (NASDAQ:GYRE) shares gapped up prior to trading on Friday. The stock had previously closed at $4.30, but opened at $4.66. Gyre Therapeutics shares last traded at $4.3980, with a volume of 119,359 shares changing hands.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the company. Wall Street Zen upgraded Gyre Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, November 7th. Zacks Research raised shares of Gyre Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Tuesday, October 6th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Gyre Therapeutics in a research note on Wednesday, November 4th. One analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Gyre Therapeutics currently has an average rating of “Reduce”.

Gyre Therapeutics Stock Down 1.7%

The business has a 50-day moving average price of $6.34 and a two-hundred day moving average price of $6.83. The company has a market capitalization of $487.23 million, a price-to-earnings ratio of -21.02 and a beta of 2.14.

Gyre Therapeutics (NASDAQ:GYRE) last issued its quarterly earnings data on Thursday, November 5th. The company reported $0.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.19. The firm had revenue of $32.93 million during the quarter, compared to analysts’ expectations of $28.40 million. Gyre Therapeutics had a negative net margin of 14.80% and a negative return on equity of 7.39%. On average, sell-side analysts anticipate that Gyre Therapeutics, Inc. will post -0.61 EPS for the current fiscal year.

Hedge Funds Weigh In On Gyre Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. acquired a new position in Gyre Therapeutics during the 2nd quarter valued at about $6,550,000. SBI Securities Co. Ltd. increased its holdings in Gyre Therapeutics by 1.8% during the 3rd quarter. SBI Securities Co. Ltd. now owns 169,717 shares of the company’s stock worth $1,244,000 after purchasing an additional 2,967 shares in the last quarter. Bank of New York Mellon Corp purchased a new position in shares of Gyre Therapeutics during the second quarter valued at approximately $414,000. Dimensional Fund Advisors LP boosted its position in shares of Gyre Therapeutics by 131.8% during the first quarter. Dimensional Fund Advisors LP now owns 25,268 shares of the company’s stock valued at $176,000 after buying an additional 14,365 shares during the last quarter. Finally, Deutsche Bank AG purchased a new position in shares of Gyre Therapeutics during the second quarter valued at approximately $118,000. Institutional investors and hedge funds own 23.99% of the company’s stock.

About Gyre Therapeutics

Gyre Therapeutics is a biopharmaceutical company focused on developing and commercializing treatments for liver and other chronic diseases. The company operates in the United States and China, including through its China-based subsidiary, Beijing Continent Pharmaceuticals. Its pipeline includes hydronidone, also known as F351, an oral drug candidate being developed for liver fibrosis associated with chronic hepatitis B. Gyre is also developing treatments for other serious conditions, including acute-on-chronic liver failure.